Alkermes plc. Shareholders' Equity
Alkermes plc. (ALKS) had Shareholders' Equity of $1.81 billion as of 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-07-28
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.81B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.75B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $1.82B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $1.73B.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $1.81B 10-Q · filed 2026-07-28 |
| 2026-03-31 | $1.75B 10-Q · filed 2026-07-28 |
| 2025-12-31 | $1.82B 10-Q · filed 2026-07-28 |
| 2025-09-30 | $1.73B 10-Q · filed 2025-10-28 |
| 2025-06-30 | $1.62B 10-Q · filed 2026-07-28 |
| 2025-03-31 | $1.51B 10-Q · filed 2026-07-28 |
| 2024-12-31 | $1.46B 10-Q · filed 2026-07-28 |
| 2024-09-30 | $1.29B 10-Q · filed 2025-10-28 |
| 2024-06-30 | $1.28B 10-Q · filed 2025-10-28 |
| 2024-03-31 | $1.25B 10-Q · filed 2025-10-28 |
| 2023-12-31 | $1.20B 10-K · filed 2026-02-25 |
| 2023-09-30 | $1.36B 10-Q · filed 2024-10-24 |
| 2023-06-30 | $1.28B 10-Q · filed 2024-10-24 |
| 2023-03-31 | $1.01B 10-Q · filed 2024-10-24 |
| 2022-12-31 | $1.04B 10-K · filed 2026-02-25 |
| 2022-09-30 | $1.04B 10-Q · filed 2023-10-25 |
| 2022-06-30 | $1.08B 10-Q · filed 2023-10-25 |
| 2022-03-31 | $1.08B 10-Q · filed 2023-10-25 |
| 2021-12-31 | $1.11B 10-K · filed 2025-02-12 |
| 2021-09-30 | $1.10B 10-Q · filed 2022-11-02 |
| 2021-06-30 | $1.10B 10-Q · filed 2022-11-02 |
| 2021-03-31 | $1.05B 10-Q · filed 2022-11-02 |
| 2020-12-31 | $1.07B 10-K · filed 2024-02-21 |
| 2020-09-30 | $1.08B 10-Q · filed 2021-10-27 |
| 2020-06-30 | $1.06B 10-Q · filed 2021-10-27 |
| 2020-03-31 | $1.06B 10-Q · filed 2021-10-27 |
| 2019-12-31 | $1.09B 10-K · filed 2023-02-16 |
| 2019-09-30 | $1.07B 10-Q · filed 2020-10-29 |
| 2019-06-30 | $1.09B 10-Q · filed 2020-10-29 |
| 2019-03-31 | $1.10B 10-Q · filed 2020-10-29 |
| 2018-12-31 | $1.17B 10-K · filed 2022-02-16 |
| 2018-09-30 | $1.15B 10-Q · filed 2019-10-23 |
| 2018-06-30 | $1.16B 10-Q · filed 2019-10-23 |
| 2018-03-31 | $1.16B 10-Q · filed 2019-10-23 |
| 2017-12-31 | $1.20B 10-K · filed 2021-02-11 |
| 2017-09-30 | $1.19B 10-Q · filed 2017-10-26 |
| 2017-06-30 | $1.20B 10-Q · filed 2017-07-27 |
| 2017-03-31 | $1.22B 10-Q · filed 2017-04-27 |
| 2016-12-31 | $1.21B 10-K · filed 2020-02-13 |
| 2016-09-30 | $1.21B 10-Q · filed 2016-11-02 |
| 2016-06-30 | $1.24B 10-Q · filed 2016-07-28 |
| 2016-03-31 | $1.27B 10-Q · filed 2016-04-28 |
| 2015-12-31 | $1.31B 10-K · filed 2019-02-15 |
| 2015-09-30 | $1.37B 10-Q · filed 2015-10-29 |
| 2015-06-30 | $1.40B 10-Q · filed 2015-07-30 |
| 2015-03-31 | $1.42B 10-Q · filed 2015-04-30 |
| 2014-12-31 | $1.40B 10-K · filed 2018-02-16 |
| 2014-09-30 | $1.33B 10-Q · filed 2014-10-29 |
| 2014-06-30 | $1.35B 10-Q · filed 2014-07-31 |
| 2014-03-31 | $1.34B 10-Q · filed 2014-04-30 |
| 2013-12-31 | $1.07B 10-K · filed 2017-02-17 |
| 2013-09-30 | $1.02B 10-Q · filed 2013-10-31 |
| 2013-06-30 | $981.94M 10-Q · filed 2013-07-25 |
| 2013-03-31 | $952.37M 10-K · filed 2016-02-25 |
| 2012-12-31 | $919.94M 10-Q · filed 2013-01-31 |
| 2012-09-30 | $885.01M 10-Q · filed 2012-11-01 |
| 2012-06-30 | $882.49M 10-Q · filed 2012-07-26 |
| 2012-03-31 | $853.85M 10-K · filed 2015-02-24 |
| 2011-12-31 | $904.85M 10-Q · filed 2012-02-02 |
| 2011-09-30 | $909.68M 10-Q · filed 2011-11-03 |
| 2011-03-31 | $392.02M 10-KT · filed 2014-02-27 |
| 2010-12-31 | $396.32M 10-Q · filed 2012-02-02 |
| 2010-09-30 | $402.09M 10-Q · filed 2011-11-03 |
| 2010-03-31 | $412.62M 10-K · filed 2013-05-23 |
| 2009-03-31 | $434.89M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |